ClariVest Asset Management’s TG Therapeutics TGTX Stock Holding History

ClariVest Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$584K	Hold	32,808	–	–	0.06%	340
2024 Q2	$584K	Sell	32,808 -65	-0.2%	-$1.04K	0.06%	340
2024 Q1	$500K	Buy	32,873 +35	+0.1%	+$558	0.05%	358
2023 Q4	$561K	Sell	32,838 -42,635	-56%	-$496K	0.03%	351
2023 Q3	$631K	Buy	75,473 +14,140	+23%	+$197K	0.03%	318
2023 Q2	$1.52M	Buy	61,333 +23,522	+62%	+$608K	0.08%	169
2023 Q1	$569K	Buy	+37,811	New	+$574K	0.03%	366
2021 Q3	–	Sell	-13,790	Closed	-$534K	–	824
2021 Q2	$534K	Buy	13,790 +30	+0.2%	+$1.18K	0.02%	422
2021 Q1	$663K	Buy	13,760 +869	+7%	+$41.8K	0.02%	362
2020 Q4	$670K	Buy	+12,891	New	+$436K	0.02%	331

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClariVest Asset Management's TGTX Position: Q3 2024 in Review

ClariVest Asset Management held its TG Therapeutics (TGTX) position steady in Q3 2024 at 32,808 shares worth $584K. The position accounts for 0.06% of the portfolio, ranked #340.

ClariVest Asset Management first reported a position in TGTX in Q4 2020 and has held it in 10 quarters since. The position peaked at $1.52M in Q2 2023. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

ClariVest Asset Management held 32,808 shares of TG Therapeutics worth $584K as of Q3 2024.
ClariVest Asset Management left its TG Therapeutics share count unchanged in Q3 2024.
TG Therapeutics made up 0.06% of ClariVest Asset Management's portfolio in Q3 2024, its #340 holding.
ClariVest Asset Management first reported a position in TG Therapeutics in Q4 2020 and has held it in 10 quarters since.
ClariVest Asset Management's TG Therapeutics position peaked at $1.52M in Q2 2023.
308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.